Averting inflammation by targeting the cytokine environment. Nature reviews

Molecular Biomedicine, Institute of Integrative Biology, ETH Zürich, Wagistrasse 27, 8952 Zürich, Switzerland.
Nature Reviews Drug Discovery (Impact Factor: 41.91). 09/2010; 9(9):703-18. DOI: 10.1038/nrd2805
Source: PubMed


Cytokines are key instigators and regulators of immune responses and therefore hold great potential as targets for new therapeutic strategies. However, the selection of which cytokines to target, and in particular the identification of which cytokines regulate the rate-limiting steps of disease pathways, is crucial to the success of such strategies. Moreover, balancing the need for ablating pathological inflammatory responses and simultaneously maintaining the ability to control infectious agents is a key consideration. Recent advances in our understanding of cytokine networks, as well as technical progress in blocking cytokines in vivo, are likely to be a source for new drugs that can control chronic inflammatory diseases.

Download full-text


Available from: Martin F Bachmann
    • "For instance, agents produced by means of biological processes frequently involving recombinant DNA technology are expensive. More importantly , they lack oral availability and often show inefficient delivery to target tissues in vivo (Kopf et al., 2010). By controlling the signalling pathways involved in tissue-specific inflammation, small molecules remain an effective approach for immunomodulatory drug development and repurposing (Thomson et al., 2009; Sundberg et al., 2014). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Drugs targeting the immune system such as corticosteroids, antihistamines and immunosuppressants have been widely exploited in the treatment of inflammatory, allergic and autoimmune disorders during the second half of the 20th century. The recent advances in immunopharmacological research made available new classes of clinically relevant drugs. These comprise protein kinase inhibitors and biologics, such as monoclonal antibodies that selectively modulate the immune response not only in cancer and autoimmunity but also in a number of additional human pathologies. Likewise, more effective vaccines utilising novel antigens and adjuvants are valuable tools for the prevention of transmissible infectious diseases and for allergen-specific immunotherapy. Consequently, immunopharmacology is presently considered as one of the expanding fields of pharmacology. Immunopharmacology addresses the selective regulation of immune responses and aims to uncover and exploit beneficial therapeutic options for typical and non-typical immune system-driven unmet clinical needs. While in the near future a number of new agents will be introduced, improving effectiveness and safety of those currently in use is imperative for all researchers and clinicians working in the fields of immunology, pharmacology and drug discovery. The newly formed ImmuPhar ( is the Immunopharmacology Section of the International Union of Basic and Clinical Pharmacology (IUPHAR, ImmuPhar provides a unique international expert-lead platform aiming to dissect and promote the growing understanding of immune (patho)physiology. Moreover, it challenges the identification and validation of drug targets and lead candidates for the treatment of many forms of debilitating disorders, including, among others, cancer, allergies, autoimmune and metabolic diseases. This article is protected by copyright. All rights reserved.
    No preview · Article · Jul 2015 · British Journal of Pharmacology
  • Source
    • "In the present work, proton nuclear magnetic resonance ( 1 H NMR) spectroscopy was used for a full characterization of flavonoids from lemongrass leaf infusion. Additionally, the antiinflammatory activity of lemongrass isolated compounds was investigated in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages by measuring the production of pro-inflammatory mediators that raise and maintain inflammation, such as nitric oxide (NO) and cytokines, namely interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α (Fortin, McDonald, Fülöp, & Lesur, 2010; Kopf, Bachmann, & Marsland, 2010). Structure–activity relationships of luteolin glycosides were also disclosed. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Flavonoids from lemongrass – Cymbopogon citratus (DC.) Stapf – leaves infusion, a commonly consumed beverage for the treatment of inflammatory-related conditions, were investigated in this work. Luteolin O-, C- and O,C-glycosides were isolated and identified by nuclear magnetic resonance, being the cassiaoccidentalin B structure fully characterized for the first time in lemongrass. The anti-inflammatory activity of luteolin and its glycosides was evaluated in lipopolysaccharide-stimulated macrophages. Luteolin glycosides demonstrated less cytotoxicity than luteolin itself. Although glycosylation decreases luteolin anti-inflammatory properties, being higher to C-glycosylation, an inhibitory effect on inflammatory mediator production (nitric oxide and IL-1β) was verified for the luteolin 7-O-β-glucopyranoside, without cytotoxic effects. Therefore, luteolin glycosides from lemongrass infusion are evidenced as a less toxic alternative to current anti-inflammatory drugs with promising use in pharmaceutical and food supplement industries. Additionally, this work establishes structure–activity relationships, which constitutes valuable information in the design of anti-inflammatory luteolin glycosides devoid of toxicity.
    Full-text · Article · Sep 2014 · Journal of Functional Foods
  • Source
    • "These results suggested that the existence of a BPA-cytokines axis in the regulation of macrophages function. Dysregulated TNF-a and IL-6 production from macrophages at local disease sites have been considered to be the major contributors to the development of inflammatory diseases [16] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Exposure to environmental endocrine-disrupting chemical Bisphenol-A (BPA) is often associated with dysregulated immune homeostasis, but the mechanisms remain unclear. In the present study, the effects of BPA on the cytokines responses of human macrophages were investigated. Treatment with BPA increased pro-inflammation cytokines tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) production, but decreased anti-inflammation cytokines interleukin-10 (IL-10) and transforming growth factor- (TGF-) production in THP1 macrophages, as well as in primary human macrophages. BPA effected cytokines expression through estrogen receptor α/β (ER α/β)-dependent mechanism with the evidence of ER α/β antagonist reversed the expression of cytokines. We also identified that activation of extracellular regulated protein kinases (ERK)/nuclear factor B (NF-B) signal cascade marked the effects of BPA on cytokines expression. Our results indicated that BPA effected inflammatory responses of macrophages via modulating of cytokines expression, and provided a new insight into the link between exposure to BPA and human health.
    Preview · Article · Aug 2014 · Biochemical and Biophysical Research Communications
Show more